scorer

[ad_1] (BFM Bourse) – The “monalizumab” molecule developed by French biotechnology and acquired by AstraZeneca aims to simultaneously boost the activity of two types of immune cells against cancer. The launch of a new clinical trial triggers a $ 50 million landmark payment at Innate, bringing the total amount received at this stage to $ …

Innate Pharma: Half a billion revenue approaching Innate Pharma’s top scorer Read More »